Revolution Medicines, shared on LinkedIn:
”We’re pleased to announce the U.S. FDA has granted Breakthrough Therapy Designation to our RAS(ON) multi-selective inhibitor in combination with gemcitabine and nab-paclitaxel for previously untreated metastatic pancreatic adenocarcinoma (PDAC), a treatment setting in which the combination is being investigated.
This latest designation further supports our broad RAS(ON) approach to addressing some of the most difficult-to-treat cancers and reflects the urgent need for new first-line treatment options for people with metastatic PDAC.”
Quoting Alan Sandler, M.D., Chief Development Officer of Revolution Medicines:
“This Breakthrough Therapy Designation underscores the significant unmet need for people with metastatic pancreatic adenocarcinoma and recognizes the importance of advancing new treatment options earlier in the treatment journey.”
You can also read:
Daraxonrasib at ASCO 2026: The Pancreatic Cancer Moment That Brought the Room to Its Feet
